Aptose Biosciences Inc

Aptose Biosciences — Investor Presentation (January 2023)

36 slides from Aptose Biosciences's investor presentation, Jan 6, 2023

  1. Slide 1: Aptose Corporate Presentation January 2023

    P R E C I S I O N O N C O L O G Y F O R T H E R A P I E S O F T O M O R R O W Aptose Corporate Presentation January 2023 NASDAQ: APTO TSX: APS I n c o r p o r a t i n g c l i n i c a l d a t a f r o m 2 0 2 2 A S H A n n u a l M e e t i n g

  2. Slide 2: Disclosure

    Disclosure 2 This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or invitation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/or assets of

  3. Slide 3: Precision Oncology Company Developing Oral Kinase Inhibitors to Treat Hematologic Malignancies

    Precision Oncology Company Developing Oral Kinase Inhibitors to Treat Life - threatening Hematologic Malignancies Expect near term value creation as monotherapy in deep R/R AML populations of high unmet need Expect long term value creation as ideal TKI for doublet/triplet combination therapy in 1L/2

  4. Slide 4: Why Tuspetinib Can Address the Greatest Needs of AML Patients

    Tuspetinib Treats AML Disease Heterogeneity 4 Why We Believe Tuspetinib Can Address the Greatest Needs of AML Patients and Achieve ≥ $1B Commercial Success

  5. Slide 5: Targets Clinically Validated Kinases in Oncogenic Signaling Pathways

    Tuspetinib Targets Clinically Validated Kinases in Oncogenic Signaling Pathways Growth Factor Receptors C - KIT MUT JAK PI3K Ras RSK AKT S6K PI3K / AKT / mTOR / S6K pathway MAPK / ERK pathway mTOR Cell Growth and Proliferation SYK STAT STAT JAK RAF MEK ERK NPM1c MUT Excessive levels of FLT3 ligand b

  6. Slide 6: Creating Near Term Value: Ideal TKI Monotherapy for Accelerated Approval in R/R AML

    Tuspetinib Creating Near Term Value Ideal TKI Monotherapy for Accelerated Approval in R/R AML Who Failed Prior FLT3i Tuspetinib Accelerated Development May Offer x Value creation in 2023 and beyond x First approval in AML indication x Well tolerated therapy x Bridge to stem cell transplant x Longer

  7. Slide 7: Creating Near and Long Term Value: Triplet Therapy in 1L AML

    Tuspetinib Creating Near Term and Long Term Value Tuspetinib Ideal Safe and Broadly Active TKI for Triplet Therapy in 1L AML HMA Hypomethylating Agent Accelerated Proliferation Altered Gene Expression Avoid Cell Death Venetoclax BCL - 2 inhibitor FLT3i - TKI that Inhibits Proliferation Pathways Canc

  8. Slide 8: US Sales Potential in AML Could Reach ≥ $1B

    Tuspetinib US Sales Potential in AML Could Reach ≥ $ 1B Potential Annual Sales ≥ $1 B PRIOR FLT3 INHIBITOR FAILURES Superior Monotherapy for Accelerated Approval MAINTENANCE THERAPY Maintain Patients Long Term MRD - negative CR DOUBLET/TRIPLET COMBINATION Place R/R Patients into MRD - NEGATIVE CR TR

  9. Slide 9: Phase 1/2 Clinical Trial Emerging Clinical PK & Safety Data

    Tuspetinib Phase 1/2 Clinical Trial 9 Emerging Clinical PK & Safety Data

  10. Slide 10: APTIVATE Phase 1b/2 Expansion Trial Ongoing with Once Daily Oral Tuspetinib

    APTIVATE Phase 1b/2 Expansion Trial Ongoing with Once Daily Oral Tuspetinib in R/R AML Patients with Adverse Mutations Phase 1a Dose Escalation • Doses from 20 mg to 200 mg • Once daily oral dosing of a tablet • Demonstrated safety / tolerability • Dose - related pharmacokinetics • Antileukemic acti

  11. Slide 11: Tuspetinib Phase 1/2 Study in R/R AML Dose Escalation & Exploration Completed

    11 Tuspetinib Phase 1/2 Study in R/R AML Dose Escalation & Dose Exploration Completed PART B DOSE EXPLORATION (42 Pts Dosed) PART A DOSE ESCALATION (18 Pts Dosed) Cohort 6 200 mg QD Completed Cohort 5 160 mg QD Completed Cohort 4 120 mg QD Completed Cohort 3 80 mg QD Completed Cohort 2 40 mg QD Comp

  12. Slide 12: Phase 1/2 Study in R/R AML: Patient Profiles

    Tuspetinib Phase 1/2 Study in R/R AML: Patient Profiles • As of October 6, 2022, 60 patients have been treated across 6 dose levels (20, 40, 80, 120, 160, and 200 mg) in Dose Escalation (Part A) and Dose Exploration (Part B) at 8 sites in the US and Korea , Republic of (South). • Patients treated in

  13. Slide 13: Delivers Safety and Broad Therapeutic Window

    Tuspetinib Delivers Safety and Broad Therapeutic Window Broad Therapeutic Window as a Single Agent in R/R AML Patients Data filtered through: 06OCT2022 13 Data from 2022 ASH Annual Meeting • Safety Profile Favorable to Date ― No drug - related myelosuppression ― No drug related AE of QT c prolongati

  14. Slide 14: Clinical Pharmacodynamic Biomarkers: Hitting the Targets

    Tuspetinib Phase 1/2 Clinical Trial 14 Clinical Pharmacodynamic Biomarkers │ “Hitting the Targets”

  15. Slide 15: Tuspetinib Targets Clinically Validated Kinases in Oncogenic Signaling Pathways

    Growth Factor Receptors C - KIT MUT JAK PI3K Ras RSK AKT S6K PI3K / AKT / mTOR / S6K pathway MAPK / ERK pathway mTOR MYC Cell Growth and Proliferation SYK STAT STAT JAK RAF MEK ERK NPM1c MUT Excessive levels of FLT3 ligand bind to FLT3 Receptor (WT & Mutated) SYK JNK Pwy BTK Pwy NFkB Direct Inhibiti

  16. Slide 16: Biomarkers: Inhibition of Phospho-FLT3 and Phospho-STAT5 by Patient Plasma

    0.001 - 20 0 20 40 60 80 100 % pSTAT5 Inhibition 0.001 - 20 0 20 40 60 80 100 % pFLT3 Inhibition Tuspetinib Biomarkers: Inhibition of Phosho - FLT3 and JAK/Phospho - STAT5 by Patient Plasma with a PIA Reporter Assay → Hits Targets & Only Partial Inhibition Required Abbreviation: PIA, plasma inhibito

  17. Slide 17: Monotherapy Delivers Blast Reductions in AML Patients

    Tuspetinib Monotherapy Delivers Blast Reductions in AML Patients 17

  18. Slide 18: Waterfall Plot of Bone Marrow Blast Reductions from Baseline

    18 Tuspetinib : Waterfall Plot of Bone Marrow Blast Reductions (Percent Change) from Baseline For Patients Assigned to 80 mg, 120 mg and 160 mg Dose Levels • Bone Marrow Blast Reductions • CRs achieved when blast clearance accompanied by full recovery of normal blood cells • Observed broadly across

  19. Slide 19: Emerging Clinical Response Data Potential Superior AML Therapy

    Tuspetinib Emerging Clinical Response Data Potential Superior AML Therapy 19

  20. Slide 20: R/R AML Patients Achieving Clinical Responses with Tuspetinib Monotherapy

    R/R AML Patients Achieving Clinical Responses with Tuspetinib Monotherapy Swimmer Plot of Responses Reported to Date Data from 2022 ASH Annual Meeting 20 Abbreviation: CR, complete response; CRh, complete response with partial hematologic recovery; CRi, complete response with incomplete hematologic

  21. Slide 21: Monotherapy Clinical Responses Across R/R AML Patients with Diverse Adverse Mutations

    Tuspetinib Monotherapy Clinical Responses Across R/R AML Patients with a Diversity of Adverse Mutations (Disease Heterogeneity) Patient Important Mutations FLT3 Status Dose Level Best Response Bridged to HSCT 1 TP53 WT 80mg CR No 2 NRAS RUNX1 ITD 80mg CRh Yes 3 NRAS BCOR U2AF1 SETBP1 WT 160mg CR Tx

  22. Slide 22: Case Study Vignettes of r/r AML Patients Responding to Tuspetinib

    Case Study Vignettes of r/r AML Patients Responding to Tuspetinib 22

  23. Slide 23: Case Study: CR in FLT3-WT / NRAS-Mutant R/R AML Patient

    Tuspetinib Case Study CR in FLT3 - WT / NRAS - Mutant R/R AML Patient 23 Data from 2022 ASH Annual Meeting R/R AML S2601 FLT3 - WT NRAS - mutated BCOR - mutated, U2AF1 - mutated, SETBP1 - mutated Cytogenetics: Normal Demographics 55 - year - old male Diagnosis at Study Entry Refractory AML with MDS

  24. Slide 24: Case Study: CR in FLT3-WT / TP53-Mutant R/R AML Patient

    R/R AML S2203 FLT3 - WT TP53 - Mutated Cytogenetics: Complex Karyotype Demographics 60 - year - old Male Diagnosis at Study Entry Refractory AML with MDS - related changes 70.8% bone marrow blasts at diagnosis Prior Therapies • Induction chemotherapy (cytarabine / daunorubicin) • Salvage therapy (cy

  25. Slide 25: Case Study: CR in FLT3-ITD / Prior-FLT3i Failure R/R AML Patient

    R/R AML S2220 FLT 3 - ITD Prior FLT 3 i Failure MLL - PTD , RUNX 1 - mutated Cytogenetics : Normal Demographics 49 - year - old Female Diagnosis at Study Entry Relapsed AML 66% bone marrow blasts at diagnosis Prior Therapies • Induction therapy (cytarabine / daunorubicin / midostaurin ) • Consolidat

  26. Slide 26: Case Study: CR in FLT3-TKD / Prior FLT3i Failure R/R AML Patient

    R/R AML S1301 FLT3 - TKD Prior FLT3i Failure RUNX1 - mutated, SF3B1 - mutated, RB1 - mutated Cytogenetics: Normal Demographics 67 - year - old Female Diagnosis at Study Entry Refractory AML 40% bone marrow blasts at diagnosis Prior Therapies • Induction therapy (cytarabine / daunorubicin / midostaur

  27. Slide 27: Going Forward

    Tuspetinib Going Forward 27

  28. Slide 28: Global Dose Expansion Trial Planned to Support Registrational Trials

    Tuspetinib Global Dose Expansion Trial Planned to Support Registrational Trials for Accelerated Approval and Drug Combination Trials for Broad Commercialization Doublet Combo Phase 2 Randomized Study R/R AML in 2L, FLT3 mutant – Tus vs. Tus/VEN vs. GILT Triplet Combo Phase 2 - 3 Randomized Study 1L

  29. Slide 29: APTIVATE Trial Timeline 2023

    Apr May Jun Jul Aug Sep Oct Nov Dec APTIVATE Trial delivers clinical response data to support protocol preparations and submission for initiation of a Monotherapy Ph 2 Registrational Trial to Support Accelerated Approval Ph 1/2 Dose Escalation & Exploration Trial 20, 40 , 80 , 120 , 160 , 200mg APTI

  30. Slide 30: APTIVATE Trial Delivering Value Creating Milestones in 2023

    Tuspetinib APTIVATE Trial Delivering Value Creating Milestones in 2023 2H 2023 : Potential Accelerated Approval path identified for Doublet Phase 2 Trial with Tus/Ven in R/R AML 2H 2023 : Triplet Phase 2 Trial initiation with “all oral” Tus/Ven/HMA in 1L AML Tuspetinib as Monotherapy 1Q 2023 : EOP1

  31. Slide 31: Monotherapy for Treatment of R/R FLT3 MUT AML Patients, Prior FLT3i Failures

    Tuspetinib Monotherapy for Treatment of R/R FLT3 MUT AML Patients │ Prior FLT3i Failures 31

  32. Slide 32: Likely Bar for Tuspetinib Accelerated Approval in R/R FLT3 MUT AML

    Likely Bar for Tuspetinib Accelerated Approval in R/R FLT3 MUT AML│Prior FLT3i Failures 32 • Gilteritinib FLT3i Approved with CR/CRh = 21% in 2L FLT3 MUT AML Patients • FDA Review: Interim CR/CRh = 21% based on data from the First Interim Analysis of the ADMIRAL trial • Gilteritinib approved • USPI

  33. Slide 33: Safely Delivers Monotherapy Responses Across Diverse AML Populations

    Tuspetinib Safely Delivers Monotherapy Responses Across Diverse AML Populations Example AML Populations with Adverse Mutations • TP53 - mutant • RAS - mutant • NPM1 - mutant - /+ FLT3 - mutant • FLT3 - mutant • FLT3 - mutant failed prior FLT3i therapy % of AML Patients 8 - 10% 15 - 40% 30% / 15% 25

  34. Slide 34: Tuspetinib Best in Class TKI for AML: Comparison to Other Agents

    TUSPETINIB Best in Class TKI for AML : Targets FLT3 + SYK + JAK - 1/2 + C - KIT Comparison to Other Approved or Investigational Agents Tuspetinib Gilteritinib Quizartinib Emavusertib Revumenib Ziftomenib Lanraplenib MOA / Targets SYK, JAK1/2 FLT3 ITD/ TKD/WT c - KIT MUT FLT3 ITD/TKD FLT3 ITD IRAK4/F

  35. Slide 35: Precision Oncology Company Developing Oral Kinase Inhibitors to Treat Hematologic Malignancies

    Precision Oncology Company Developing Oral Kinase Inhibitors to Treat Life - threatening Hematologic Malignancies Tuspetinib │ Safely Treats AML Disease Heterogeneity │ Orphan Drug Status │ Fast Track Status Disease heterogeneity is the greatest obstacle to the effective treatment of AML Tuspetinib

  36. Slide 36: Aptose Biosciences

    APTGSE BIOSCIENCES

Aptose Biosciences — Investor Presentation (January 2023) on 6ix